Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)

Status: Recruiting
Phase: Phase 2
Diagnosis: Lymphoma
NCT ID: NCT02038933 (View complete trial on
DFCI Protocol ID:


The purpose of this study is to determine whether Nivolumab is effective in the treatment of DLBCL in patients that have failed or are ineligible for ASCT


Conducting Institutions:
Brigham and Women's Hospital, Dana-Farber Cancer Institute

Overall PI:
Philippe Armand, MD, Dana-Farber Cancer Institute

Site-responsible Investigators:

Dana-Farber Cancer Institute: Kathleen McDermott,

Eligibility Criteria

For more information regarding BMS clinical trial participation, please visit Inclusion Criteria: - Confirmation of relapsed or refractory DLBCL or transformed lymphoma (TL) - Eastern Cooperative Oncology Group (ECOG) performance status of 0 -1 - At least one lesion that measures >1.5 cm - Prior therapy and screening lab criteria must be met - Appropriate contraceptive measures must be taken Exclusion Criteria: - Known central nervous system (CNS) lymphoma - History of interstitial lung disease, prior malignancy, active autoimmune disease, positive test for hepatitis B or hepatitis C virus - Prior allogeneic stem cell transplant (SCT), chest radiation ≤ 24 weeks from study drug, ≥1000 mg of Carmustine Bis-chloroethylnitrosourea (BCNU) as part of pre-transplant conditioning regimen, prior treatment with drug targeting T-cell costimulation or immune checkpoint pathways - Women who are breastfeeding or pregnant
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)

    • Quick access:
      Appointments as soon as the next day for new adult patients

    • For children:
      888-733-4662 (888-PEDI-ONC)

    • Request Appointment Online